Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Comparative Evaluation of Contrast-Enhanced MRI and FDG-PET/CT in Spinal Pathology: Image Quality and Short-Term Renal-Hematologic Safety

5 giugno 2026 aggiornato da: Ahmed Elgendi, Cairo University

This prospective comparative observational study evaluates image quality characteristics and short-term physiological effects associated with contrast-enhanced magnetic resonance imaging (MRI) and fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in patients with cervical and lumbar spinal pathologies.

A total of 120 adult participants undergo either contrast-enhanced MRI or FDG-PET/CT as part of routine clinical evaluation. Image quality is assessed using quantitative metrics, including signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR), as well as qualitative Visual Grading Analysis (VGA) performed by blinded radiologists. Short-term physiological effects are evaluated using blood urea nitrogen (BUN), estimated glomerular filtration rate (eGFR), and hemoglobin measurements obtained before imaging and 48 hours after imaging.

The study aims to compare image quality characteristics and short-term physiological parameters associated with these imaging modalities and to examine the influence of age group and spinal region on imaging performance.

Panoramica dello studio

Descrizione dettagliata

Background and Rationale

Magnetic resonance imaging (MRI) and fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) are widely used imaging modalities for the evaluation of cervical and lumbar spinal disorders. MRI primarily provides high-resolution anatomical information, whereas FDG-PET/CT provides metabolic and functional information that may assist in the assessment of inflammatory, infectious, degenerative, and neoplastic spinal conditions. Although both modalities are routinely used in clinical practice, differences in image quality characteristics and short-term physiological effects associated with imaging procedures remain areas of interest.

Study Design

This study is a prospective comparative observational study designed to evaluate image quality characteristics and short-term physiological effects associated with contrast-enhanced MRI and FDG-PET/CT in adult patients with cervical or lumbar spinal pathologies. A total of 120 participants are included, with 60 participants undergoing contrast-enhanced MRI and 60 participants undergoing FDG-PET/CT according to routine clinical indications and standard institutional workflows.

The study is non-interventional. No experimental treatments, investigational drugs, or deviations from standard clinical care are introduced. All imaging procedures are performed according to established institutional protocols and manufacturer recommendations.

Study Population

Eligible participants are adults with clinically suspected or confirmed cervical or lumbar spinal pathology requiring advanced imaging evaluation. Conditions may include degenerative, inflammatory, infectious, neoplastic, traumatic, or post-surgical spinal disorders.

Imaging Procedures

MRI examinations are performed using a 3 Tesla scanner equipped with a dedicated spinal coil. Standard spinal imaging protocols include sagittal and axial T1-weighted and T2-weighted sequences. Intravenous gadolinium-based contrast administration is performed according to institutional guidelines and standard clinical practice.

FDG-PET/CT examinations are performed following standard patient preparation procedures, including fasting requirements and blood glucose assessment. Intravenous administration of 18F-fluorodeoxyglucose (FDG) is followed by image acquisition using routine clinical PET/CT protocols. CT acquisition is used for attenuation correction and anatomical localization according to institutional practice.

Image Quality Assessment

Quantitative image quality assessment includes measurement of signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) using standardized regions of interest. Measurements are performed using predefined image analysis procedures to ensure consistency across participants.

Qualitative image quality assessment is performed using Visual Grading Analysis (VGA). Independent blinded radiologists evaluate image quality using predefined criteria related to anatomical detail, tissue contrast, lesion conspicuity, image noise, and overall diagnostic usability.

Physiological and Safety Assessments

Short-term physiological effects associated with imaging procedures are evaluated using laboratory measurements obtained before imaging and 48 hours after imaging. Laboratory assessments include blood urea nitrogen (BUN), estimated glomerular filtration rate (eGFR), and hemoglobin concentration.

Routine safety monitoring is performed according to institutional standards. Adverse events associated with contrast administration or imaging procedures are documented and managed according to standard clinical protocols.

Subgroup Analyses

Prespecified subgroup analyses evaluate image quality metrics according to spinal region (cervical versus lumbar) and age group (50 years or younger versus older than 50 years). These analyses are intended to explore potential differences in imaging performance across clinically relevant patient subgroups.

Study Objectives

The primary objectives are to compare quantitative image quality metrics between contrast-enhanced MRI and FDG-PET/CT and to evaluate qualitative image quality using blinded radiologist assessment.

Secondary objectives include assessment of short-term changes in renal and hematologic laboratory parameters following imaging procedures performed as part of routine clinical care.

Ethics

The study is conducted in accordance with applicable ethical principles, institutional policies, and approved research protocols. Institutional Review Board approval has been obtained, and informed consent procedures are implemented as required by the approved protocol and applicable regulations.

Tipo di studio

Osservativo

Iscrizione (Effettivo)

120

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Giza Governorate
      • Giza, Giza Governorate, Egitto, 43556
        • (MISR University Scientific Research Innovation Committee,

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Bambino
  • Adulto
  • Adulto più anziano

Accetta volontari sani

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Participants will be recruited from the general population through community outreach, advertisements, and screening visits. Individuals who meet the eligibility criteria will be invited to participate.

Descrizione

Inclusion Criteria:

  • Age 18 years or older.
  • Clinically suspected or confirmed cervical or lumbar spinal pathology.
  • Presence of symptoms suggestive of spinal disease, including radiculopathy, localized spinal pain, neurological deficits, or suspected metastatic involvement.
  • Referred for diagnostic evaluation with contrast-enhanced MRI or FDG-PET/CT according to routine clinical indications.
  • Availability of baseline clinical and laboratory data, including renal function assessment.
  • Ability to provide informed consent.

Exclusion Criteria:

  • Severe renal impairment (eGFR <30 mL/min/1.73 m²) or acute kidney injury.
  • Known hypersensitivity to gadolinium-based contrast agents or 18F-FDG.
  • Contraindications to MRI, including non-compatible metallic implants or severe claustrophobia.
  • Pregnancy or breastfeeding.
  • Uncontrolled diabetes mellitus (blood glucose >200 mg/dL at the time of PET/CT examination).
  • Active systemic infection or inflammatory condition requiring immediate treatment.
  • Inability to complete the required imaging procedures.
  • Incomplete clinical, laboratory, or imaging data required for study evaluation.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Coorti e interventi

Gruppo / Coorte
patient allocation to MRI (n=60) and FDG-PET/CT (n=60) groups with stratification by spinal re-gion

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Quantitative Image Quality Assessment
Lasso di tempo: Assessed at the imaging visit (up to 1 day).

Secondary Outcome Measure 1

Outcome Measure:

Blood Urea Nitrogen (BUN)

Description:

Change in serum blood urea nitrogen concentration following imaging procedures.

Time Frame:

Baseline (pre-imaging) and 48 hours post-imaging.

Unit of Measure:

mg/dL

Secondary Outcome Measure 2

Outcome Measure:

Estimated Glomerular Filtration Rate (eGFR)

Description:

Change in estimated glomerular filtration rate following imaging procedures.

Time Frame:

Baseline (pre-imaging) and 48 hours post-imaging.

Unit of Measure:

mL/min/1.73 m²

Secondary Outcome Measure 3

Outcome Measure:

Hemoglobin Level

Description:

Change in hemoglobin concentration following imaging procedures.

Time Frame:

Baseline (pre-imaging) and 48 hours post-imaging.

Unit of Measure:

g/dL

Secondary Outcome Measure 4

Outcome Measure:

Visual Grading Analysis (VGA) Score

Description:

Qualitative image quality assessment performed by blinded radiologists to evaluate anatomical clarity, lesion delineation, image contrast, and

Assessed at the imaging visit (up to 1 day).

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Comparative Evaluation of Image Quality and Short-Term Physiological Effects of Contrast-Enhanced MRI versus FDG-PET/CT in Cervical and Lumbar Spine Pathologies
Lasso di tempo: For image quality assessment: At the time of imaging For short-term physiological effects (BUN, eGFR, hemoglobin): Baseline (pre-imaging) and 48 hours post-imaging

Short-term physiological effects of contrast-enhanced MRI and FDG-PET/CT, assessed via changes in renal function and hematologic parameters:

Serum blood urea nitrogen (BUN) at baseline and 48 hours post-imaging Estimated glomerular filtration rate (eGFR) at baseline and 48 hours post-imaging Hemoglobin levels at baseline and 48 hours post-imaging Qualitative image evaluation, measured by Visual Grading Analysis (VGA) performed by blinded radiologists to assess anatomical clarity, lesion delineation, and overall diagnostic usability.

For image quality assessment: At the time of imaging For short-term physiological effects (BUN, eGFR, hemoglobin): Baseline (pre-imaging) and 48 hours post-imaging

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

  • References 1. Altman, D.G. Practical Statistics for Medical Research (1st ed.); Chapman and Hall/CRC, 1990. 2. Andreucci, M.; Solomon, R.; Tasanarong, A. Side effects of radiographic contrast media: pathogenesis, risk factors, and pre-vention. Biomed Res Int. 2014, 2014, 741018. 3. Association, W.M. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Jama 2013, 310, 2191-4. 4. Bajwa, H.; Sritharan, T.; Botha, T.; et al. Assessment of cervical spine CT by an image quality audit using qualitative and quantitative methods. J Med Imaging Radiat Oncol. 2025, 69, 7-16. 5. Benchoufi, M.; Matzner-Lober, E.; Molinari, N.; et al. Interobserver agreement issues in radiology. Diagn Interv Imaging 2020, 101, 639-41. 6. Beyer, T.; Bailey, D.L.; Birk, U.J.; et al. Medical Physics and Imaging-A Timely Perspective. Front. Phys. 2021, 9, 634693. 7. Boellaard, R.; Delgado-Bolton, R.; Oyen, W.J.; et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015, 42, 328-54. 8. Boos, N.; Rieder, R.; Schade, V.; et al. The Imaging characteristics of Magnetic Resonance Imaging, Work Perception, and Psychosocial Factors in Identifying Symptomatic Disc Herniations. Spine 1995, 20. 9. Boriani, L.; Zamparini, E.; Albrizio, M.; et al. Spine Infections: The Role of Fluorodeoxyglucose Positron Emission Tomography (FDG PET) in the Context of the Actual Diagnosis Guideline. Curr Med Imaging 2022, 18, 216-30. 10. Brinjikji, W.; Luetmer, P.H.; Comstock, B.; et al. Systematic literature review of imaging features of spinal degeneration in asymptomatic populations. AJNR Am J Neuroradiol. 2015, 36, 811-6. 11. Brown, T.F.; Yasillo, N.J. Radiation safety considerations for PET centers. J Nucl Med Technol. 1997, 25, 98-102; quiz 4-5. 12. Burmeister, H.P.; Baltzer, P.A.; Möslein, C.; et al. Visual grading characteristics (VGC) analysis of diagnostic image quality for high resolution 3 Tesla MRI vol

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

5 aprile 2025

Completamento primario (Effettivo)

3 novembre 2025

Completamento dello studio (Effettivo)

1 gennaio 2026

Date di iscrizione allo studio

Primo inviato

31 maggio 2026

Primo inviato che soddisfa i criteri di controllo qualità

5 giugno 2026

Primo Inserito (Effettivo)

10 giugno 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 giugno 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

5 giugno 2026

Ultimo verificato

1 giugno 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi